Eight-year experience of using HTA in drug reimbursement: South Korea

Bae, Eun Young; Hong, Jae‐Hee; Kwon, Hye-Young; Suhyun, Jang; Lee, Hye Jae; Bae, Sung Heui; Yang, Bong Min

doi:10.1016/j.healthpol.2016.03.013

Cited by 38 publications

(49 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For new drugs, the listing and pricing scheme has been well established since the DERP in 2007. Specifically, a recent evaluation stated that value for money of new drugs has been well reflected in reimbursement decisions, and has contributed to improving transparency and rationality [7]. In contrast, drug price negotiations confirmed the need for improvements in transparency and consistency [11].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Drug Pricing in South Korea

Kwon

Godman

2017

Appl Health Econ Health Policy

Self Cite

View full text Add to dashboard Cite

Background: Between 2000 and 2013, spending on medicines in Korea increased by 275.3%. In order to curb this trend, several pricing policies and measures were introduced. Objectives: This study reviews these policies and their implications. Methods: Review of pricing regulations as well as a literature review. Results: New medicines must now undergo both a reimbursement assessment and price negotiations. The reimbursement of new medicines is based on their cost-effectiveness. The prices of new medicines are subsequently fixed through negotiations between the payer, the National Health Insurance Service, and the relevant manufacturer. Generic drugs are automatically priced via a new standard methodology. Re-pricing mechanisms were complicated and now redundant. Conclusions: Simple and efficient measures rather than complex and inefficient measures are needed to maintain the value for money principle for new medicines as well as achieve financial efficiency through price competition among multiple s sourced drugs, building on the experiences in other countries.

show abstract

Section: Discussionmentioning

confidence: 99%

“…These include cost-effectiveness, clinical usefulness and budget impact. Until 2007, almost all medicines that received market approval from the Ministry of Food and Drug Safety had been listed as reimbursed medicines within the NHI with little consideration for budget impacts and/or cost-effectiveness [7].…”

Section: New Drug Pricingmentioning

confidence: 99%

Drug Pricing in South Korea

Kwon

Godman

2017

Appl Health Econ Health Policy

Self Cite

View full text Add to dashboard Cite

show abstract

“…For example, interministerial collaboration has taken place in Thailand, South Korea, and China. 61,62 China's 2009 health system reform plan followed four years of consultation and collaboration with stakeholders, including service providers, policy analysts, think tanks, academic institutions, and international organizations. 7 In Cambodia, the Ministry of Health worked with the Department of Drugs and Food to collaborate with a wide range of agencies internal and external to the government, including law enforcement agencies (national and international), nongovernmental organizations, and the WHO to reduce the circulation of poor-quality medicines.…”

Section: Function 4: Collaboration and Coalition Buildingmentioning

confidence: 99%

Governance Functions to Accelerate Progress toward Universal Health Coverage (UHC) in the Asia-Pacific Region

Yeoh

Johnston

Chau

et al. 2019

Health Systems & Reform

View full text Add to dashboard Cite

Many countries in the Asia-Pacific region have committed to universal health coverage (UHC), which is reflected in both their political commitment and the governance actions they have taken in steering their health systems toward the goals of universal access to care and protection from financial hardship. Countries throughout the region are at different stages of development and have different political and governance contexts, which in turn shape how they pursue governance for UHC. This article reviews the governance functions deployed in the Asia-Pacific and finds that, in many, governance reforms adapting their health systems toward greater regulation, accountability, oversight, and stewardship of the health system have been part of their wider move toward UHC. Countries have not followed a set pattern, but shared aspects include establishing UHC as a goal in national policy making and priority setting; the creation of new roles and/ or new institutions within the health system; establishing systems of monitoring and evaluation; and putting in place mechanisms to facilitate collaboration and ensure greater accountability. The relationship between governance and UHC in the Asia-Pacific region is found to be complex, negotiated, and shaped by a number of factors in both the internal and external environment, including broader governance arrangements in the public sector (institutional changes and decentralization are particularly prominent factors) and the ability of governments to implement policies and steer the health system.

show abstract

“…To compare HTA policy in Hong Kong to overseas commonwealth countries, information related to the new drug decision-making process for HTA agencies with a centralized drug review process [1] were reviewed and retrieved from official English guidelines published on the website of advisory bodies. Decision-making processes of neighboring Asian countries such as China [8,15,16], South Korea [6][7][8], Japan [9], Thailand [8] and Malaysia [10] were only reported in published literature but not on the official advisory body websites. Therefore, these countries are not included in the comparisons.…”

Section: Methodsmentioning

confidence: 99%

“…Drug appraisal and the review process involves an initial assessment of clinical evidence and health economic evidence for certain developed countries, which leads to recommendations or the decision to reimburse new drugs based on appraisal of the best-available evidence [1]. This approach to review has been adopted in the Hong Kong drug listing formulary system and new drug reimbursement systems in many developed commonwealth countries [2][3][4][5] and some Asian countries such as South Korea [6][7][8], Japan [9], Thailand [8], and Malaysia [10].…”

Section: Manuscript Text Introductionmentioning

confidence: 99%